Synergistic Induction of Apoptosis in High-Risk DLBCL by BCL2 Inhibition with ABT-199 Combined With Pharmacologic Loss of MCL1

Better treatments are needed for patients with diffuse large B-cell lymphoma (DLBCL) at high risk of failing standard therapy. Avoiding apoptosis is a hallmark of cancer, and in DLBCL the redundantly functioning anti-apoptotic proteins BCL2 and MCL1 are frequently expressed. Here, we explore drugs t...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Lingxiao, Pongtornpipat, Praechompoo, Tiutan, Timothy, Kendrick, Samantha L., Park, Soyoung, Persky, Daniel O., Rimsza, Lisa M., Puvvada, Soham D., Schatz, Jonathan H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4526343/
https://www.ncbi.nlm.nih.gov/pubmed/25882699
http://dx.doi.org/10.1038/leu.2015.99

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4526343/
https://www.ncbi.nlm.nih.gov/pubmed/25882699
http://dx.doi.org/10.1038/leu.2015.99

Ejemplares similares